Acute Myelogenous Leukemia (AML) Clinical Trial
Official title:
Pilot Trial of Two Dose Levels of Thymoglobulin as Part of a Myeloablative-Conditioning for a Human Leukocyte Antigen (HLA) Identical Matched Related Donor (MRD) Stem Cell Transplant (SCT) With Cyclosporine (CSa) as Post-transplant Graft vs. Host Disease (GvHD) Prophylaxis
Verified date | March 2015 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This study involves the use of a drug called Thymoglobulin, which is approved in the USA to
treat kidney transplant rejection and in Canada to treat and to prevent kidney transplant
rejection. Thymoglobulin is not approved for the treatment or prophylaxis of graft versus
host disease in bone marrow transplantation. This study is to evaluate two (2) doses of
Thymoglobulin and its safety and effectiveness when used with a "myeloablative" conditioning
regimen prior to receiving a stem cell transplant (also called bone marrow transplantation)
from a matched, related donor.
A myeloablative regimen is typically composed of chemotherapy and radiation and destroys the
subject's existing bone marrow.
Subjects meeting all inclusion and exclusion criteria and who have a relative with matching
(genetically similar) stem cells who are also willing to donate them (i.e.
matched-related-donor) are eligible to participate in this study. Following myeloablative
therapy, the donor's cells are then transplanted (i.e. infused) into the subject's blood
stream.
One of the most common complications of this type of transplant is graft-versus-host disease
(GvHD). This is a condition where the transplanted donor cells attack the transplant
recipient's body. Treatments, such as cyclosporine, are used to minimize the risk of GvHD
following stem cell transplantation.
To enter this study, subjects must be having a matched-related donor stem cell transplant.
If a subject qualifies for entry into this study, he/she will be assigned to receive
Thymoglobulin at a dose of 4.5 mg/kg or 8.5 mg/kg. The treatment assignment is random and is
not chosen by the subject or their physician.
Subjects are admitted to the hospital for the transplant procedure and are treated with
Thymoglobulin over 3-5 days just prior to receiving the donor stem cells. The subject will
also receive standard GvHD prophylaxis with cyclosporine. Methotrexate, which is commonly
used by transplant centers to minimize the risk of GvHD, will not be used in this study.
Subjects will be monitored during treatment with Thymoglobulin and during the transplant
hospitalization. Additional subject monitoring occurs at month 1, 100 days and 6 months
following the transplant.
Approximately 60 study subjects from approximately 14 transplant centers in the United
States and Canada will be enrolled.
Status | Completed |
Enrollment | 60 |
Est. completion date | April 2006 |
Est. primary completion date | April 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Subject has an HLA-A, -B and -DRB1 identical related donor and must be fully matched at Class II. A high resolution molecular HLA typing (at least 4 digits) is mandatory for HLA Class II and optional for HLA Class I - Subject has confirmed diagnosis of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) with acute myeloid leukemia (including secondary leukemia) in first complete remission (CR2) or acute lymphoid in CR1 or CR2. - Subject is >= 18 and <= 55 years of age. - Subject is receiving a myeloablative-conditioning regimen - Men and women of childbearing age potential agree to practice an acceptable and reliable form of contraception during the study. Women must not be lactating or pregnant, and must have a negative serum pregnancy test. - Subject has been fully informed and has signed an IRB-approved informed consent form. - Subject is willing and able to follow study procedures for the 6 months post-transplant. - The subject must be serologically negative for human immunodeficiency virus (HIV). - Subject agrees to be followed for possible long-term safety outcomes for up to 12 months post-transplant. - Subject has an ECOG performance score of 0-2. - Subject has a creatinine of < 2.0mg/dL or creatinine clearance of > 50mL/min. - Subject has an ejection fraction of >= 40% - Subject has a serum bilirubin of < 2mg/dL. Exclusion Criteria: - Subject is receiving fludarabine, a non-myeloablative regimen, or other purine analogues as part of the conditioning regimen. - Subject is receiving an ex vivo engineered or processed graft (CD34+ enrichment, T-cell depletion, etc.) - Subject has documented uncontrolled central nervous system (CNS) disease. - Subject is expected to receive or has received methotrexate for GvHD prophylaxis. - Subject has alanine aminotransferase (ALT)or aspartate aminotransferase (AST) level of > 3x the upper limit of normal range within 3 weeks prior to transplant. - Subject has used any experimental agent within 30 days prior to the date of signing the informed consent. - Subject is receiving or has received a bone marrow transplant from a donor who has positive serology for HIV, hepatitis B virus(HBV), hepatitis C virus (HCV) or syphilis. - Subject has a known contraindication to administration of rabbit anti-thymocyte globulin. - Subject is currently abusing drugs or alcohol or, in the opinion of the Investigator, is at high risk for poor compliance. - Subject, who in the opinion of the Investigator, has significant medical or psychological problems that warrants exclusion. Examples of significant problems include, but are not limited to, morbid obesity or severe cardiac disease. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
Canada | Ottawa Hospital - General Campus | Ottawa | Ontario |
Canada | Princess Margaret Hospital, University Health Network | Toronto | Ontario |
United States | Emory University Hospital | Atlanta | Georgia |
United States | University of Alabama-Birmingham Hospital | Birmingham | Alabama |
United States | Dana Farber Cancer Institute Dana 1B11 | Boston | Massachusetts |
United States | Massachusetts General Hospital Cox Bldg Room 640 | Boston | Massachusetts |
United States | Beth Israel Deaconess Medical Center KS121 | Brookline | Massachusetts |
United States | Duke University Medical Center | Durham | North Carolina |
United States | Shands at the University of Florida, Division of Hematology/Oncology | Gainesville | Florida |
United States | Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey |
United States | UCLA Medical Center | Los Angeles | California |
United States | The Nebraska Medical Center | Omaha | Nebraska |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | Washington University School of Medicine | St. Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Genzyme, a Sanofi Company |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Grade II to IV acute GvHD in the first 100 days after transplant. | 100 days | Yes | |
Secondary | Incidence of treatment related adverse events and serious adverse events at 100 days and 6 months post transplant | 100 days and 6 months | Yes | |
Secondary | Patient survival at 100 days and 6 months after transplant | 100 days and 6 months | Yes | |
Secondary | transplant related mortality at 100 days or 6 months after transplant | 100 days and 6 months | Yes | |
Secondary | severity and outcomes of acute GvHD | 100 days & 6 mos | Yes | |
Secondary | any events of infection at 100 days and 6 months after transplant | 100 days and 6 months | Yes | |
Secondary | incidence (or absence) of mucositis | continuous | Yes | |
Secondary | how many days in the first month after transplant certain types of narcotics are used to reduce pain | 30days | Yes | |
Secondary | whether the subject's blood counts after transplant reach a stable level and how quickly | Continuous | Yes | |
Secondary | incidence of re-hospitalization in the first 6 months after transplant | 6 months | Yes | |
Secondary | any recurrence of the subject's leukemic disease, and how long the subject was able to stay in remission | Continuous | Yes | |
Secondary | incidence and severity of chronic GvHD, and the extent, after 100 days and 6 months after transplant | 100 days and 6 months | Yes | |
Secondary | Disease free survival | 100 days and 6 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00528983 -
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
|
Phase 1 | |
Completed |
NCT01221857 -
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT01451437 -
Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)
|
Phase 1 | |
Completed |
NCT01885897 -
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
|
Phase 1/Phase 2 | |
Recruiting |
NCT05884333 -
Cord Blood Transplant in Adults With Blood Cancers
|
Phase 2 | |
Terminated |
NCT01873495 -
Omacetaxine for Consolidation and Maintenance
|
Phase 2 | |
Terminated |
NCT03600909 -
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
|
Phase 2 | |
Active, not recruiting |
NCT02061800 -
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00943553 -
A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
|
Phase 2 | |
Terminated |
NCT01113502 -
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)
|
Phase 1/Phase 2 | |
Terminated |
NCT01050764 -
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
|
Phase 1/Phase 2 | |
Terminated |
NCT00672152 -
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation
|
Phase 1 | |
Recruiting |
NCT03260101 -
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
|
||
Terminated |
NCT02200380 -
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
|
Phase 2 | |
Active, not recruiting |
NCT02240537 -
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
|
Phase 1 | |
Completed |
NCT01527838 -
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
|
Phase 1 | |
Terminated |
NCT00779480 -
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)
|
Phase 1 | |
Completed |
NCT01768845 -
Unrelated Umbilical Cord Blood (UBC)Transplantation
|
N/A | |
Terminated |
NCT01265199 -
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
|
Phase 1 | |
Completed |
NCT02793544 -
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 |